Gathering the record
Relay is organizing the evidence and source boundaries.
CNTF-derived experimental peptide
P21 commonly refers to P021, an experimental peptide derived from a ciliary neurotrophic factor region and studied in animal models of learning and neurodegeneration.
60-Second Overview
Start with what it is, why it matters, what research has shown, and what remains unknown. The science follows after the orientation.
Start here. These four answers explain why the compound matters before the page introduces the deeper science.
P21 commonly refers to P021, an experimental peptide derived from a small region of ciliary neurotrophic factor. The name can be ambiguous, so sequence identity matters.
Researchers use P021 in animal models to explore learning, neurogenesis, synaptic function, and Alzheimer-like pathology. These models can test biological hypotheses before human exposure.
In transgenic and aged mice, P021 improved selected learning measures and changed pathology, neurogenesis, or synaptic markers. Some studies delivered it in feed or specialized experimental formulations. No controlled administered-human study was located.
A standardized human product identity, pharmacokinetics, brain exposure, target engagement, clinical outcomes, neurologic safety, interactions, and long-term effects remain unknown. Mouse behavior and surrogate markers cannot establish prevention or treatment of cognitive decline in people.
The research depth, routes, studies, and primary sources below explain how Relay knows—and where the evidence stops.
Research context
Published research has investigated this compound using the following study designs.
These records explain what researchers did. They are not instructions, recommendations, or a transferable protocol.
Published research investigated P021 in transgenic and aged mouse models, measuring learning behavior alongside neurogenesis, synaptic, and disease-like pathology markers.
Reported study administration—not a recommendation.
Research at a glance
Evidence depth, confidence, and route context explain how Relay knows—not what anyone should do.
Animal and mechanistic evidence only; marketed naming can be ambiguous.
Research depth describes how large and mature the overall record is. It does not tell you whether the results were positive.
Human identity, pharmacokinetics, target engagement, clinical outcomes, and longer-term neurologic safety.
Confidence describes how reliable and consistent the conclusions are. It can be high for one outcome and low for another.
The strongest evidence type shows what the best-supported conclusions are actually based on.
Human findings are more directly relevant than animal or laboratory results, but they still apply only to the populations and outcomes studied.
Route-specific record
These are exposures used in cited research for a specific route and population—not an instruction for an individual.
Half-life describes how long it takes the measured amount in the body to fall by half. It is not a dosing recommendation.
Evidence can change by administration method. Findings from one route should not automatically be applied to another.
Evidence boundary: No verified controlled study administered P021 to human participants. Animal behavior and surrogate brain markers cannot establish human cognition benefit, disease prevention, exposure, or safety. Amounts shown describe cited research exposure—not a dosage recommendation.
Detailed evidence
Start with the strongest supported conclusion and its main uncertainty. Claim-level records below show how the evidence changes by question, population, route, formulation, and study design.
No controlled administered-human study of P021 was located.
This is the strongest supported conclusion in the current human evidence—not a summary of every claim made about the compound.
Human identity, pharmacokinetics, target engagement, clinical outcomes, and longer-term neurologic safety.
Keeping the main uncertainty visible prevents an early or promising finding from looking more settled than it is.
Questions people bring to the evidence
Research questions—not promises of benefit.
This is the strongest human-evidence boundary in the current record.
Mechanistic findings explain biological plausibility; they do not establish a human outcome.
Relay keeps this uncertainty visible rather than converting it into a prediction.
The safety snapshot reflects the studied record and its limitations.
Regulatory and identity status determine how the evidence should be interpreted.
Mechanisms
P021 was designed to retain neurotrophic signaling while limiting parent-protein liabilities. Published outcome evidence is preclinical and should not be confused with the unrelated p21 cell-cycle protein.
A plausible mechanism can explain why a study was attempted. It does not prove that the compound improves a human outcome.
Studies
Study arms are reported for transparency. They describe what researchers did in a defined record and do not transfer across identities, routes, formulations, or populations.
A later trial phase can ask a more mature question, but it does not guarantee a positive result, regulatory approval, or relevance outside the studied population.
Controlled animal studies
Mouse models
P021 improved selected learning and pathology measures in transgenic and aged mouse models.
Study administration: P021 in feed or experimental formulations
Limitations: Animal-model and formulation findings do not establish human outcomes.
Animal and laboratory study
Rodents and neural systems
Endpoints were not fully described in the current record.
Preclinical studies reported neurogenesis and synaptic markers alongside behavioral outcomes.
Study administration: Not stated in the current record.
Limitations: Surrogate markers and animal behavior do not establish clinical benefit.
Safety snapshot
Current evidence cannot yet resolve: Human identity, pharmacokinetics, target engagement, clinical outcomes, and longer-term neurologic safety.
No direct evidenceAn absence of adequate evidence is not evidence of benefit, harm, or equivalence.
Open sourceThe current record does not support a reliable common-versus-uncommon frequency split.
Evidence boundaryUnder-detected or under-reported events must not be described as rare.
No source-qualified compound-specific warning or contraindication is encoded in the current record.
Evidence boundaryPreclinical; no FDA-approved P21/P021 product. Human identity, pharmacokinetics, target engagement, clinical outcomes, and longer-term neurologic safety.
The current record does not identify a reliable compound-specific pattern of events that caused study discontinuation.
Evidence boundaryThis is an evidence gap, not proof that discontinuations did not occur.
No compound-specific patient-facing urgent-action threshold is established in the current Relay record.
Evidence boundaryRelay does not infer emergency guidance from study discontinuations, mechanism, or incomplete adverse-event reporting.
Community
Built by the community
Every structured report adds useful context about research setup, outcomes, and unwanted effects as the community dataset grows.
Publicly anonymous by default. Your account keeps reports editable and helps reduce duplicate submissions.Sources
PMID 20600002
PMID 26114951